NCT03775278View on ClinicalTrials.gov

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 17, 2018

Primary Completion Date

July 24, 2019

Study Completion Date

April 7, 2020

Conditions
Otherwise Healthy Overweight or Obese
Interventions
DRUG

PHP-303

Investigational drug

OTHER

Placebo

Matching placebo

Trial Locations (1)

66212

Vince & Associates Clinical Research, Inc., Overland Park

Sponsors

Lead Sponsor

pH Pharma
All Listed Sponsors
lead

pH Pharma

INDUSTRY

NCT03775278 - A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects | Biotech Hunter | Biotech Hunter